Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study
Authors:
Open Access
- 19 October 2016
- journal article
- Published by Springer Nature in The Journal of Antibiotics
- Vol. 70 (2) , 166-173
Abstract
The purpose of this study was to validate the mutant selection window (MSW) hypothesis in vitro and in vivo with Escherichia coli and Pseudomonas aeruginosa exposed to fosfomycin. Two standard strains of Gram-negative bacteria, those are E. coli ATCC 25922 and P. aeruginosa ATCC 27853, were exposed to fosfomycin at concentrations below MIC, between the MIC and the mutant prevention concentration (MPC), and above the MPC in Luria-Bertani broth and in a tissue-cage infection model, respectively. With the in vitro time-kill studies, there were bacterial re-growth and emergence of resistance thereafter for both strains at antibiotic concentrations of × 4, × 8 and × 16 MIC. In our animal model, the loss in susceptibility of P. aeruginosa at fosfomycin concentrations fluctuated between the lower and upper boundaries of the MSW. In contrast, the emergence of resistant mutants of E. coli was not observed in vivo, regardless of fosfomycin dosage. Interestingly, the in vitro-isolated resistant mutants of E. coli showed a decreased growth rate compared with the susceptible parental strains, whereas no fitness cost in P. aeruginosa was observed. The emergence of antibiotic resistance is shaped by several factors. MSW theory may not apply to all antimicrobial-pathogen combinations. Before it can be used as a framework for the design of antimicrobial therapy, the existence of the window must be demonstrated not only in vitro but also in vivo.Keywords
This publication has 34 references indexed in Scilit:
- Testing the mutant selection window hypothesis with Escherichia coli exposed to levofloxacin in a rabbit tissue cage infection modelEuropean Journal of Clinical Microbiology & Infectious Diseases, 2013
- Resistance Development of Cystic Fibrosis Respiratory Pathogens When Exposed to Fosfomycin and Tobramycin Alone and in Combination under Aerobic and Anaerobic ConditionsPLOS ONE, 2013
- Testing the mutant selection window in rabbits infected with methicillin-resistant Staphylococcus aureus exposed to vancomycinJournal of Antimicrobial Chemotherapy, 2012
- Mutant Prevention Concentration-Based Pharmacokinetic/Pharmacodynamic Indices as Dosing Targets for Suppressing the Enrichment of Levofloxacin-Resistant Subpopulations of Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2011
- Compensation of Fitness Costs and Reversibility of Antibiotic Resistance MutationsAntimicrobial Agents and Chemotherapy, 2010
- Assessing the Emergence of Resistance: The Absence of Biological Cost In Vivo May Compromise Fosfomycin Treatments for P. aeruginosa InfectionsPLOS ONE, 2010
- Mutant prevention concentration of tigecycline for carbapenem-susceptible and -resistant Acinetobacter baumanniiThe Journal of Antibiotics, 2009
- Exploring the role of the immune response in preventing antibiotic resistanceJournal of Theoretical Biology, 2009
- In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Microbiology Profiling Studies with Staphylococci and StreptococciAntimicrobial Agents and Chemotherapy, 2008
- Fosfomycin: Use Beyond Urinary Tract and Gastrointestinal InfectionsClinical Infectious Diseases, 2008